Navigation Links
Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
Date:9/13/2011

PRINCETON, N.J., Sept. 13, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b, international study of PSI-7977 and PSI-938, two nucleotide analog polymerase inhibitors for the treatment of chronic hepatitis C (HCV). The QUANTUM trial will evaluate interferon-free regimens of PSI-7977 400mg QD and PSI-938 300mg QD with and without ribavirin over 12 or 24 weeks in patients with HCV who have not been treated previously. The trial will also evaluate the use of PSI-938 monotherapy.

"We are encouraged by the early efficacy and safety data being generated with our nucleotide analogs, PSI-7977 and PSI-938," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer.  "The QUANTUM trial is the first interferon-free, all-nucleotide study with an SVR endpoint. The ability to include all HCV genotypes was supported by data from the NUCLEAR study and the interferon free arms of the ELECTRON trial. Data from ELECTRON are expected later this year."

About the Phase 2b QUANTUM Trial This study is designed to enroll approximately 450 patients with chronic HCV of all viral genotypes who have not been treated previously. The primary endpoint of the trial will be sustained virological response (SVR24). Patients will be equally randomized across the following arms:

  • PSI-938 only
  • PSI-938 and PSI-7977
  • PSI-7977 and ribavirin
  • PSI-938, PSI-7977, and ribavirin

    • All arms will be study for both 12 and 24 weeks with a placebo control of 24 weeks.

  • Placebo for 24 weeks

    • HCV patients will be stratified by IL28B status and baseline HCV RNA to ensure balance across cohorts. Cirrhotic and non-cirrhotic patients will be enrolled in the study.

    Additional details on this and all ongoing Pharmasset sponsored trials can be found at

    SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3

    Related medicine technology :

    1. Pharmasset Announces Two-for-One Forward Stock Split
    2. Pharmasset to Present at Canaccord Genuity Growth Conference
    3. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
    4. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
    5. Pharmasset to Present at Two Upcoming Investor Conferences
    6. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
    7. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
    8. Pharmasset to Webcast an Investor Event From the EASL Meeting
    9. Pharmasset to Present at Three Upcoming Investor Conferences
    10. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
    11. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2013)... -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it ... enrollment required for its Phase I trial to evaluate the ... Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common ... no Severe Adverse Effect (SAE) reported. The Phase ... NIH under number NCT01828762 (click here to view) ...
    (Date:5/22/2013)... May 22, 2013 PRNewswire – iBio, ... of a vaccine candidate for the newly emerged ... laboratory using the iBioLaunch™ platform. This validation milestone ... initial antigen sequence information to purification of recombinant ... ) The iBioLaunch platform eliminates the ...
    (Date:5/22/2013)... TEL AVIV, Israel , May 22, 2013 /PRNewswire/ ... "Company") (TASE, NASDAQ: EMITF) announced today, further to the ... filed a motion with the Tel Aviv ... of its unsecured creditors and shareholders for the approval ... debt pursuant to a plan of arrangement (the "Arrangement") ...
    Breaking Medicine Technology:Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 2Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 3iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza 2Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court 2Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court 3
    ... Pa., Aug. 24, 2011 ePharmaSolutions announced the successful ... for a top five global pharmaceutical company on more ... client deployment scheduled for September 2011. Clinical ... process for sponsors, study sites and third party vendors ...
    ... Fla., Aug. 24, 2011 China Nuvo Solar ... various sales channels are all reporting success that is ... lines. The Company,s plan of action to sell through ... with medical co-ops and other third party outsourcing solutions ...
    Cached Medicine Technology:ePharmaSolutions Announces the Deployment of its Enterprise Clinical Trial Portal for Two Global Biopharmaceutical Companies 2China Nuvo Solar Target Acquisition SurgLine Reports on Marketing Progress 2China Nuvo Solar Target Acquisition SurgLine Reports on Marketing Progress 3
    (Date:5/22/2013)... and Los Angeles, CA (PRWEB) May 22, 2013 ... the board, The J. M. Smucker Company, and ... Achievement Awards yesterday at the GS1 General Assembly and ... California. Mr. Smucker and Mr. Wegman were recognized for ... GS1 Standards - the most broadly used supply chain ...
    (Date:5/22/2013)... May 22 (HealthDay News) -- Children and teens exposed ... likely to develop cancer, according to a large, long-term ... a group of 10,000 young people who each had ... be expected to occur within 10 years, according to ... doctors should carefully weight the risks to patients when ...
    (Date:5/22/2013)... available in German . ... Foundation) is establishing 11 new Research Training Groups to ... was made by the relevant Grants Committee in Bonn. ... to the new programmes for an initial period of ... 11 new Research Training Groups, the Grants Committee approved ...
    (Date:5/22/2013)... run, encouraging a baby to finish the last ounce in ... Though the calories soon burn off, a bad habit remains. ... Forste found that clinical obesity at 24 months of age ... overweight at age two, it puts you on a trajectory ... and adolescence and as an adult," said Forste. "That,s a ...
    (Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal ... the previous version used prior to 2010, the 7-valent ... study published today in Vaccine . , The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
    Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Children Who Have CT Scans May Face Higher Cancer Risk 2Health News:DFG establishes 11 new research training groups 2Health News:DFG establishes 11 new research training groups 3Health News:DFG establishes 11 new research training groups 4Health News:DFG establishes 11 new research training groups 5Health News:Overeating learned in infancy, study suggests 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
    ... care at community health clinics especially women ... cardiologist than those who receive primary care at hospitals, ... the American Heart Association . , Researchers from the ... Medical School reviewed the electronic medical records of 9,761 ...
    ... April 27 Robert J. Gould, a behavioral ... nation,s most successful social marketing campaigns, has been ... by Partnership,s board of directors was announced today ... board."Rob,s unique combination of behavioral science expertise, proven ...
    ... a worrisome rise in childhood obesity, Florida school districts ... but there is little research available to determine if ... a $2.2 million grant from the National Institutes of ... a Florida State University College of Medicine researcher will ...
    ... today that, working with the UN Refugee Agency (UNHCR), it will send ... African countries. , ... Washington, D.C. (Vocus) April 27, 2009 -- The ... Refugee Agency (UNHCR), it will send over 346,000 life-saving bed nets to ...
    ... April 27 50,000 hand addressed letters were sent to ... Notre Dame officials, urging ND Grads to fight ... sent 50,000 letters to Alumni from ,88 and back. (Older ... post cards are designed to be sent to Vatican and ...
    ... Company (Nasdaq: STAA ) today announced that it will release financial ... May 5, 2009 after ... host a conference call and webcast on Tuesday, ... 1:30 p.m. Pacific to discuss the Company,s first quarter results ...
    Cached Medicine News:Health News:Patients at community health clinics less likely to be referred to cardiologist 2Health News:Patients at community health clinics less likely to be referred to cardiologist 3Health News:Robert J. Gould Named President at Partnership for Prevention 2Health News:FSU researcher wins $2.2 million grant to study childhood obesity 2Health News:FSU researcher wins $2.2 million grant to study childhood obesity 3Health News:UN Foundation to Help Protect More than a Million Refugees from Malaria in Africa 2Health News:50,000 Letters Sent to Notre Dame Alumni Re: Obama; In Letter, Bishop Gracida Urged Former U.S. Ambassador to the Vatican Mary Ann Glendon to Refuse Award 2Health News:STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call 2
    ... Biotech Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked ... detection and quantitative determination of IgG antibody ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
    ELISA kit for Varicella-zoster IgM....
    ... Varicella-Zoster Virus (VZV) IgG Enzyme-Linked Immunosorbent Assay ... quantitative determination of IgG antibody to VZV ... may be used for the determination of ... may be used to demonstrate seroconversion or ...
    ... Zeus Scientific, Inc. Mumps IgG ELISA test ... of Mumps IgG antibody in human serum. ... results of this test, together with other ... of immune status, and/or aid in the ...
    Medicine Products: